ZF English

Zentiva posts sales worth over 38m euros in H1

02.08.2006, 18:51 17

Zentiva Romania (former Sicomed) witnessed sales worth 38.4 million euros in the first six months of this year, a 14-fold increase against the similar period of last year, according to the six-month report of the Czech group Zentiva. Not taking into consideration the sales of the Sicomed producer, taken over last year by Zentiva, the portfolio made up of drugs of the Czech company totalled sales worth some 23 million euros, representing an almost eight-fold increase against the first six months of 2005.
"The growth was generated by the fact that an optimal development strategy was implemented, as well as by our launching new products (Tralgit, Fokusin, Coxtral) on the Romanian market, which generated large sales to the company. The sales trend was also stimulated by Simvacard, a product whose sales in Romania exceed 50% of its total sales," stated Mariana Wencz, country manager at Zentiva.
In terms of international Zentiva brands, the best selling drugs on the local market were Simvacard and Tralgit, 54% more than last year. However, it was local brands, like Algocalmin, Antinevralgic P, Extraveral and Dicarbocalm that contributed the most to the results achieved in Romania.
As a matter of fact, Algocalmin became one of the best selling drugs of the Czech group at an international level, ranking 6th among its products, with sales worth 6.3 million euros.
"In Romania, which is now the second largest market for Zentiva, we will continue to strengthen our presence by launching increasingly more successful brands and we expect this positive trend to maintain in the future, as well," stated Zentiva's chairman, Jir? Michal.
On the other hand, Klaas Postema, general manager of pharmaceutical maker Zentiva SA Romania gave up this position yesterday, but will remain chairman of the company's Board of Directors.
"Until the appointment of a new general manager by the Board of Directors, his duties will be transferred to the specialised department managers," company representatives announced.
Klaas Postema's contract with Zentiva expired at the end of July, with his main duty being to complete the integration of the company's operations in Romania.
He did not express a wish to extend his contract with Zentiva, therefore the company will seek a replacement in the upcoming period. "For the time being, we do not know who will take Mr. Postema's place. Preliminary data will only become available on August 7, when there will be a board meeting to discuss this issue. What is sure is that the appointment of the new general manager will have to be approved by the Board of Directors," says Wencz.
Regarding his departure, Postema said, "I am sure that in its current structure, Zentiva will continue to be leader of the generic drug market in Romania."


Zentiva Romania

Sales were 14 times higher in the first half than in the same time last year
The portfolio of Zentiva drugs, excluding Sicomed's, generated sales of about 23 million euros, almost eight times higher than in H1, 2005
Best-selling international Zentiva brands in Romania were Simvacard and Tralgit, a 54% increase on last year.
Largest contribution to the results in Romania came from local brands like Algocalmin, Antinevralgic P, Extraveral and Dicarbocalm

Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels

Comandă anuarul ZF TOP 100 companii antreprenoriale
AFACERI DE LA ZERO